1. Home
  2. CWBC vs ENTA Comparison

CWBC vs ENTA Comparison

Compare CWBC & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CWBC

Community West Bancshares

HOLD

Current Price

$22.21

Market Cap

464.9M

Sector

Finance

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.69

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CWBC
ENTA
Founded
1989
1995
Country
United States
United States
Employees
338
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
464.9M
374.6M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
CWBC
ENTA
Price
$22.21
$12.69
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$24.33
$20.40
AVG Volume (30 Days)
125.4K
167.2K
Earning Date
04-20-2026
02-09-2026
Dividend Yield
2.16%
N/A
EPS Growth
N/A
29.93
EPS
N/A
N/A
Revenue
N/A
$102,814,000.00
Revenue This Year
$39.39
$5.91
Revenue Next Year
$17.64
N/A
P/E Ratio
$12.13
N/A
Revenue Growth
N/A
16.48
52 Week Low
$15.57
$4.09
52 Week High
$25.72
$17.15

Technical Indicators

Market Signals
Indicator
CWBC
ENTA
Relative Strength Index (RSI) 32.30 41.26
Support Level $22.03 $12.09
Resistance Level $24.47 $15.52
Average True Range (ATR) 0.59 0.78
MACD -0.10 -0.18
Stochastic Oscillator 9.44 7.57

Price Performance

Historical Comparison
CWBC
ENTA

About CWBC Community West Bancshares

Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the Company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: